The vascular dysfunction manifest by the stroke prone spontaneously hypertensive rat (SHRSP) encompasses a reduced bioavailability of nitric oxide (NO) with a subsequent effect on vascular responses when compared with its normotensive reference strain, Wistar-Kyoto (WKY). The aim of this study was to express a recombinant endothelial nitric oxide synthase (eNOS) gene in the carotid artery of the SHRSP in order to restore the bioavailability of NO to that seen in the WKY. Molecular and functional analysis of an adenovirus containing eNOS (AdCMVeNOS) was carried out in vitro using Western blotting, immunocytochemical analysis and the Greiss reaction. AdCMVlacZ, an adenovirus expressing a reporter gene was used as a control. Experiments were then carried out on 12-week-old SHRSP and WKY rats by infusion, in vivo, of either AdCMVeNOS or AdCMVlacZ virus into the left carotid artery with the right contralateral acting as an untreated control. A significant increase in eNOS expression was observed in the intact endothelium of arteries infused with AdCMVeNOS as compared with their controls as shown by Western blotting Figure 1 Response to PE in the presence of L-NAME in carotid arteries from (a) WKY and (b) SHRSP infected with AdCMVeNOS (ț) and contralateral controls (˼). (c) Response to PE in the presence of L-NAME in vessels from SHRSP infected with AdCMVlacZ (ț) and their contralateral controls (˼). Results expressed as response to PE relative to KCl in the presence of L-NAME-response to PE relative to KCl in the absence of L-NAME. and immunohistochemistry. Endothelial function was measured, ex vivo, 24 h after the infusion, by incubating the carotids in the absence and presence of the NOS inhibitor N G -nitro-arginine-methyl ester (L-NAME) (100 M) and measuring the response to phenylephrine relative to the predetermined response to KCl (Figure 1 ). The area under the curve of the concentration responses to phenylephrine (1 × 10 −9 − 3 × 10 −6 M) in the absence and presence of L-NAME showed increased basal NO bioavailability in the carotid arteries, from SHRSP, infused with AdCMVeNOS compared to control (n = 6 for each; P = 0.0067; 95% CI, 0.86 to 3.27; Figure 1b ). The increase in tension in the presence of L-NAME in the AdCMVlacZ infused vessels was similar to that in their control vessels (n = 6; P = 0.87, Figure  1c ) and there was no difference in tension between the AdCMVeNOS infused WKY vessels and their controls (n = 5; P = 0.17; Figure 1a ). In conclusion, this study shows that AdCMVeNOS is an effective tool for vascular gene transfer in the SHRSP and that it can restore NO bioavailability to that observed in the WKY strain.
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The positive inotropic effect of NO donors and the relationship to NO release kinetics

DA Sarkar, P Vallance and SE Harding
Centre for Clinical Pharmacology & Therapeutics, University College London, 5 University Street, London WC1E 6JJ, UK Background The effect of nitric oxide (NO) donors on cardiac myocyte contractile function remains controversial with studies reporting either positive or negative inotropic effects. To investigate this paradox we assessed the response of isolated guinea pig and human myocytes to a range of structurally unrelated NO donors and examined the rate of release of NO as a possible source of variation in the observed response.
Methods Guinea pig and human myocytes were prepared by enzymatic digestion. Paced contractile amplitude was recorded at 37°C using an edge detection system sampling at 100 Hz. NO release was measured in an acellular system using oxyhaemaglobin and dual beam spectrophotometry.
Results On a background of low dose isoproterenol (0.3 nM) the contractile responses to 1-100 M Snitrosoglutathione (GSNO), S-nitroso-N-acetyl penicillamine (SNAP), glyceryl trinitrate (GTN), sodium nitroprusside (SNP) and papanonoate were recorded. Compared with isoproterenol alone, 10 M of NO donor significantly increased contraction amplitude: GSNO 72 ± 9% (mean ± s.e.m., P Ͻ 0.001, n = 6); SNAP 116 ± 23% (P Ͻ 0.01, n = 7) and papanonoate 90 ± 11% (P Ͻ 0.001, n = 6). Neither GTN or SNP produced any significant effect. The positive inotropic responses to NO donors were rapid, sustained and reversible. Exposing cells to 100 M 1H- [1, 2, 4] oxadiazolo [4,3-alpha] quinoxalin-1-one (ODQ), a soluble guanylyl cyclase inhibitor,
A membrane protein abnormality in erythrocytes from essential hypertensive (EHT) patients with abnormal Na/Li countertransport
SL Watkins, IC West, R Wilkinson and TH Thomas
Departments of Medicine and Biochemistry, Medical School, University of Newcastle-upon-Tyne, UK Abnormal Na/Li countertransport (CT) is a marker of EHT with a strong family history, metabolic abnormalities and high cardiovascular risk. The aim was to identify membrane proteins associated with Values are mean (s.e.). Both 33 kDa biotin and GAPDH (relative to actin) are absorbance units. Km is mmol Na/l. *P = 0.015, ** P = 0.004 vs NC. n = 8 for NC and 9 for EHT.
did not abolish the response to GSNO and the cGMP analogue 8Br-cGMP did not mimic it. The positive effect was unchanged in the presence of thapsigargin but reversibly inhibited by the free NO scavenger oxyhaemaglobin. Preliminary studies in ventricular myocytes isolated from human hearts showed a significant but smaller and more variable increase of contraction with GSNO (38% ± 16, P = 0.02, n = 8).
The release rates of NO from GSNO and SNP (10 M) were similar in an acellular system (50.2 ± 9.5 vs 34 ± 3 nanomoles/min −1
). However in biological systems GSNO is subject to enzymatic degradation which may greatly enhance NO release. Diethylamine/NO (DEA/NO) and detanonoate are not subject to metabolic degradation. Release rates measured at 10 M by spectrophotometry were 409 ± 115 (DEA/NO) and 58 ± 14 nanomoles/min −1 (detanonoate). Myocytes serial exposed to detanonoate then DEA/NO over a concentration range of 10 −6 -10 −4 M showed a significant increase in contraction amplitude only when treated with the faster releasing DEA/NO (124 ± 28, P = 0.0014, n = 5).
Conclusion Isolated guinea pig myocytes showed a marked positive inotropic effect with certain NO donors including GSNO. This is mediated by free NO via a mechanism independent of soluble guanylyl cyclase. Variation in response to donors may reflect their different release kinetics. The positive inotropic effect of GSNO coupled with its vasodilating and antiplatelet properties makes it of therapeutic interest. the transporter as candidates for an abnormality in EHT.
In normal erythrocytes alkylation of a thiol protein with N-ethylmaleimide (NEM) occurs rapidly in very mild conditions and causes a decrease in Km of Na/Li CT to values that are characteristic of EHT. Changes in total membrane protein (Coomassie blue stained) and thiol proteins (biotin maleimide labelled), separated by polyacrylamide gel electrophoresis, were compared with the change in Km of Na/Li CT during reaction of erythrocytes with NEM.
Two major changes in membrane protein occurred during reaction with NEM: (a) the loss of biotin maleimide labelling of a 33 kDa protein (p33) and (b) an increase in glyceraldehyde-3-phosphate dehydrogenase (GAPDH) binding to the cell membrane. These effects of NEM are both different in erythrocytes from EHT compared with normal controls (NC).
In normal controls the NEM induced increase in Background and methods Enzymes other than ACE may generate Angiotensin II (AII) in human tissues and this may account for clinically observed escape from ACE-inhibition. We have described a dual pathway for AII generation in resistance arteries from volunteers, mediated by ACE and Chymase. We hypothesised that ACE independent AII generation may be up-regulated in patients receiving chronic ACE-inhibitor therapy. Thus we studied AII generation in resistance arteries from patients with chronic heart failure (CHF, n = 10) on chronic ACE inhibitor therapy. Controls were ACE-naϊve patients with coronary heart disease (CHD, n = 10). Resistance arteries were dissected from gluteal biopsies and studied using wire myography, using the contractile response to angiotensin I (AI) as a marker of AII generation. Concentration response curves to AI were constructed in the presence of (1) vehicle, (2) chymostatin (CH, 10 −5 M), [an inhibitor of chymase], (3) enalaprilat (E, 10 −6 M), and (4) E + CH.
Angiotensin II generation by non-ACE pathways in human resistance arteries
Results
In CHD responses were similar to those in volunteers (data not shown): neither E nor CH alone inhibited AI responses, but there was a strong trend to inhibition with E + CH (P = 0.054). In CHF AI responses were inhibited by E but not by CH. Addition of CH to E resulted in greater inhibition than E alone (P = 0.0038 E vs E + CH).
Conclusions
There is a dual pathway for AII generation in resistance arteries from patients with CHF and CHD. In CHD inhibition of either ACE or chym-GAPDH is related to the decrease in p33-biotin with an initial slow GAPDH phase up to 30 sec (slope −0.16, P = 0.015) and then a more rapid phase (slope −0.45, P Ͻ 0.001). The decrease in Km of Na/Li CT with NEM treatment closely follows the decrease in p33. In EHT both Km and p33 are low so that the abnormal p33 could explain the low Km. In fact, with NEM treatment up to 30 sec, in contrast to NC, in EHT p33 increases (P Ͻ 0.01). In EHT the increase in GAPDH is abnormally rapid in the first 30 sec of NEM treatment (P = 0.04). p33 may have a role in GAPDH binding to the membrane that is abnormal in EHT and results in the low Km. Membrane bound GAPDH has important roles including membrane fusion of intracellular vesicles. ase can be overcome by shunting through the other pathway. However, in CHF, the response to AI is blunted in the presence of enalaprilat, suggesting that chymase cannot fully compensate. This may be due to down-regulation of chymase, up-regulation of ACE, or both. While ACE may be more important in CHF, further inhibition of AII generation is obtained by inhibiting Chymase, suggesting that maximal blockade of the renin angiotensin system cannot be achieved with ACE-inhibition alone. This data supports the use of angiotensin receptor antagonists, alone or in combination with ACE inhibitors, in order to fully block AII generation. Background Reduced vascular compliance in patients with hypertension results from an increase in extra-cellular matrix (ECM) protein deposition in blood vessels, leading to greater risk of myocardial infarction, stroke and renal disease. However, the pathophysiology underscoring these vascular changes is not clearly defined. Previous studies have independently implicated mechanical strain and neurohumoral mediators (ie, Angiotensin II), however, ascertaining the relative contribution of these factors could highlight novel therapeutic interventions. ECM proteins such as collagen ␣ 1 and fibronectin are abundant in the vascular matrix and identification at an experimental level has been established. This work examined the direct effect of mechanical strain on collagen ␣ 1 mRNA expression and fibronectin mRNA expression and protein synthesis by human vascular smooth muscle (VSM) cells and identified a role for Ang II in stretchinduced matrix production.
Design and methods An in vitro model for hypertension has been identified using human VSM cells subjected to varying stimuli in constant cell culture conditions (37°C, 5% CO 2 ). In one arm of this study, human VSM cells were exposed to a computer-generated continuous (12-h) cyclical mechanical strain regime designed to mimic the forces generated by blood pressure in vivo. In the second arm, human VSM cells were exposed to Angiotensin II (Ang II) at 10 −6 M for 12-h under static cell culture conditions. Both stretch and Ang II stimulated cells were treated with the Ang II receptor (AT 1 R) antagonist losartan. Static unstimulated human VSM cells served as controls. Analysis of mRNA expression was standardised with a conventional constantly expressed cellular protein (GAPDH). Cell super- We previously identified two quantitative trait loci (QTL) for blood pressure on chromosome 2 in a F2 cross derived from the stroke-prone spontaneously hypertensive rat (SHRSP) and its normotensive reference strain, the Wistar-Kyoto (WKY) rat. The aim of the present work was to begin the dissection of these QTL using a marker-assisted 'speed' congenic strategy. Eight speed congenic strains were pronatants were analysed for fibronectin synthesis by an ELISA method using a commercially available anti-fibronectin antibody.
Results
(1) Mechanical strain induced a 600% increase in collagen ␣ 1 mRNA expression and an increase in both fibronectin mRNA expression and protein synthesis compared to controls. (2) Ang II increased matrix synthesis in static VSM cells (collagen ␣1 mRNA by 110%: fibronectin mRNA by 120% and protein by 11%), which was inhibited by the Ang II receptor (AT 1 R) antagonist losartan. (3) Moreover, in the absence of exogenous Ang II, AT 1 receptor blockade attenuated this stretch-induced increase in matrix synthesis (collagen ␣1 mRNA by 51%; fibronectin mRNA by 54% and protein by 9%).
Conclusion
Both mechanical stretch and Ang II increase matrix gene expression and protein production by human VSM cells. Furthermore, AT 1 receptor blockade attenuates this response to stretch. However, the mechanism underlying this has not been fully elucidated. It might imply a stretch-induced endogenous production of Ang II by human VSM cells with Ang II acting as an autocrine factor to enhance matrix production via the AT 1 receptor. Alternatively, mechanical strain might induce upregulation of the AT 1 receptor, therefore potentiating any effect of Ang II. Fundamentally, these studies directly implicate the activation of a local vascular renin-angiotensin system in mediating the vascular response to mechanical strain. The capacity of Ang II to increase blood pressure and thus increase mechanical strain illustrates the potential existence of a renin-angiotensin system multiplier in the vessel wall of hypertensive subjects.
duced by introgressing various segments of chromosome 2 from WKY rats into the recipient SHRSP strain, and vice versa. The number of backcross generations required for each strain to achieve complete homozygosity at 83 background genetic markers in a 'best' male varied between three and five. The effect of QTL transfer on both baseline and saltloaded (1% NaCl) blood pressure were examined Objective Hypertension is associated with an increased risk of mortality from myocardial infarction and congestive heart failure. Myocardial ischaemia can result from an imbalance in cardiac systolic workload and diastolic perfusion time in the absence of overt coronary disease. Chronic hypertension impairs cardiovascular compliance which in turn disturbs pulse wave morphology leading to diminution or disappearance of the diastolic wave and augmentation (Ag) of the systolic wave. These changes can be documented by applanation tonometry (AT). AT can be utilised to quantify the systolic and diastolic pressure time intervals (SPTI and DPTI) which determines the relationship between cardiac systolic work and the time for diastolic filling of coronary arteries. The ratio DPTI/SPTI, the Buckberg ratio, is therefore an indirect measure of myocardial ischaemia.
Design and methods Using AT and sphygmocardiography Ag (%), Ag (mm Hg) and Buckberg ratios in hypertensive (systolic BP 177 ± 3 mm Hg, diastolic BP 110 ± 2 mm Hg, n = 46) and age-matched (45 ± 1 yrs vs 44 ± 2 yrs, NS) normotensive (systolic BP 111 ± 1 mm Hg, diastolic BP 73 ± 1 mm Hg, n = 46) subjects were compared. Subjects with clinical coronary heart disease were excluded.
Results
The hypertensive subjects were recruited using a radiotelemetry system and 16 128 systolic and diastolic blood pressure measurements were obtained. These were divided into day and night, separated as middle 6-h averages (10.00 pm to 4.00 am for night time) to obtain peak values for diurnal variations. Transfer of the region of chromosome 2 containing both QTL from WKY into a SHRSP genetic background significantly lowered daytime baseline systolic blood pressure for congenic males (n = 3) SP.WKY.gla2a (171 ± 1.1 mm Hg) vs SHRSP males (n = 3) (190 ± 2.9 mm Hg), 95% CI for mean difference (3.09, 35.24) and night-time systolic blood pressure for congenic males (172.6 ± 2.5 mm Hg) vs SHRSP males (197.1 ± 2.5 mm Hg), 95% CI for mean difference (24.2, 24.8); Figure 1a . In contrast, male controls for stowaway heterozygosity (SP.WKY.gla2b) presented no deviation from the blood pressure recorded for the SHRSP in daytime and night-time baseline systolic blood pressure; Figure 1b . This is the first successful demonstration of a speed congenic strategy in the dissection of blood pressure QTL in the rat.
from the Leicester Hypertension Clinic and had a significantly increased Ag (133 ± 3% vs 125 ± 3%, P Ͻ 0.05 and 12 ± 1 mm Hg vs 5 ± 1 mm Hg, P Ͻ 0.001). Differences in heart rate can influence Ag with a 4% reduction for every 10 bpm increase in heart rate. The heart rates between the two groups were different (77 ± 2 bpm in the hypertensives vs 69 ± 2 bpm in the normotensives, P Ͻ 0.01), however this difference did not account for the increase in Ag seen in the hypertensive subjects. The increase in Ag suggests a reduced vascular compliance in these young hypertensive subjects along with a significantly reduced Buckberg ratio (147 ± 5% vs 165 ± 4%, P Ͻ 0.01) indicating greater myocardial ischaemia, when compared to the agematched normotensive controls.
Conclusions
In otherwise healthy, young hypertensive subjects, we report a significant predisposition to myocardial ischaemia when compared to a well-matched normotensive control group. The association with the increase in Ag suggests that these disturbing cardiac changes are dependent on reduced vascular compliance and the resulting changes in pulse wave morphology. These results suggest that hypertensive subjects are likely to be predisposed to increased myocardial ischaemia even in the absence of overt coronary disease. Experimental studies suggest that systolic function is depressed in cardiac hypertrophy while human studies indicate that it is preserved. Experimental studies have tended to measure myocardial or myofibril function while most human investigations have assessed whole heart function by utilising endocardial measurements. However, myocardial shortening in subendocardial layers is greater than that in subepicardial layers. Therefore a theoretical mid-point in the left ventricular wall shows relative migration towards the epicardium throughout contraction. There may therefore be a discrepancy between shortening at the endocardium and the midwall. In order to assess the relationship between endocardial and midwall shortening in normal subjects and those with cardiac hypertrophy we initially assessed using echocardiography 76 patients, 38 with previously untreated hypertensive left ventricular hypertrophy and 38 control subjects. Secondly, in order to investigate the effects of treatment on midwall function 32 hypertensive patients underwent treatment with ramipril with the addition of felodipine and bendrofluazide, if required. Patients underwent echocardiography at baseline, BP control and after a further 6 months of tight BP control.
Midwall left ventricular systolic function in cardiac hypertrophy
In the first part of the study the mean cardiac output, ejection fraction and endocardial fractional shortening were similar between the baseline groups (left ventricular hypertrophy 4.3 ± 0.2 l/min, 62 ± 2%, 35 ± 1.5%; control 4.5 ± 0.2 l/min, 66 ± 1%, 37 ± 0.8% respectively) but shortening assessed at the midwall was significantly less in the left ventricular hypertrophy group (left ventricular 2.3 Systemic blood pressure levels do not influence dynamic cerebral autoregulatory responses to depressor and pressor stimuli in older people Objective Advancing age may be associated with a fall in cerebral blood flow resulting in a shift of the lower limit of static cerebral autoregulation (CA) to higher blood pressure (BP) levels though the agerelated changes in dynamic CA have not been previously studied. We wished to assess in a cohort of older people, with a wide range of systemic BP levels, the influence of pressor and depressor BP stimuli on their dynamic cerebral autoregulatory responses.
Design and methods Ninety-nine (50 female) subjects with mean age 67.1 ± 7.2 years (range 48-81 years), average 24-h ambulatory systolic BP (SBP) 134 ± 22 mm Hg (range 107-225), diastolic BP (DBP) 83 ± 13 mm Hg (range 58-130), mean arterial pressure (MAP) 98 ± 12 (range 70-146) and body mass index 27 ± 4 m/kg 2 were studied. Middle cerebral hypertrophy 17.9 ± 1.1%, control 21.6 ± 0.6%, P Ͻ 0.01). When midwall shortening was adjusted to take into account circumferential wall stress to compare stress-shortening relationships, these differences were maintained. In the treatment study, good BP control was achieved after 6 months compared with baseline (143/86 ± 2.8/1.4 vs 174/103 ± 4.1/1.9 mm Hg; P Ͻ 0.01) with significant regression of LV mass index (124 ± 3.4 vs 145 ± 3.8 g/m 2 ; P Ͻ 0.01). Endocardially assessed indices of LV systolic function were not significantly different. Cardiac output was 4.34 ± 0.19 l/min after 6 months compared with 4.48 ± 0.26 at baseline. LV fractional shortening assessed at the midwall improved with regression of LVH (21.9 ± 0.84, 18.7 ± 1.19%; P Ͻ 0.05), post treatment midwall shortening being similar to that of normal subjects.
These results show that midwall systolic function is depressed in left ventricular hypertrophy compared with normal subjects. However, left ventricular chamber function is maintained and similar to that of normal subjects. One explanation for these results is that the altered left ventricular geometry in hypertrophy allows the maintenance of endocardial systolic function in spite of depressed myocardial function. These data provide a link between the conflicting results of previous experimental and human studies. Depressed midwall shortening has been shown to be an independent predictor of an adverse outcome in hypertensive subjects, particularly in those subjects with additional LVH so the improvement with therapy is an important observation.
artery (MCA) blood flow was isonated using bilateral transcranial Doppler ultrasound and the Doppler frequency shift and measurements of pulse interval, BP and carbon dioxide partial pressure were recorded onto digital analogue tape. Dynamic depressor stimuli were obtained by the rapid deflation of bilateral thigh cuffs inflated to above or near systolic BP for 90 sec, and from spontaneous falls in BP у10 mm Hg taken from rest recordings of 5 min duration. Dynamic pressor stimuli were obtained from the rise in BP recorded on release of a lower negative pressure box in which the pressure had been reduced to achieve a sustained fall in BP of about 20 mm Hg for 5 min and also from spontaneous rises in BP у10 mm Hg taken from the rest recordings as above. Only those recordings with BP changes у10 mm Hg occurring within 200 ms of the stimulus were accepted as adequate. Dynamic auto-regulatory indexes (ARI) were calculated using Tiecks' method (Tiecks FP. Stroke 1995; 26: 1014 -1019). Least squares regression analysis was used to examine the relationship between ARI and increasing BP levels and age. Differences in ARI values between the different pressor and depressor stimuli were also tested for. Statistical significance was taken at the 5% level.
Results The average right MCA velocity was 43.5 ± 9.1 cm/s, depth 5.2 ± 0.5 cm and the average left MCA velocity was 44.4 ± 8.6 cm/s, depth 5.2 ± 0.5 cm. The autoregulatory indices are presented as the mean MCA velocity of the right and left as no significant differences were found between the two sides. There was no significant difference in ARI between pressor and depressor tests and no relation with age or systemic 24-h ABPM levels. Background The primary goal of the MRC British Genetics of Hypertension Study (MRC BRIGHT study) is to identify the major genes for high blood pressure by genomic screening in 1500 white European families based upon affected sibling pairs with essential hypertension. The families are identified using the MRC General Practice Framework and have pre-diagnosis blood pressures in the upper 5% of the blood pressure distribution and onset prior to 60 years of age. The affected sib pairs have been extensively phenotyped by trained nurses according to standard operating procedures with family history of cardiovascular disease, socio-economic status, anthropomorphic measurements, 12 lead ECG, echocardiography, biochemistry, lipids and 24-h creatinine clearance and protein loss. By April 1999, 1044 hypertensive families conforming to BRIGHT criteria had been phenotyped.
Precision of genomic screening data within the MRC British Genetics of Hypertension Study
Methods
In August 1997 we commenced genomic screening of 164 families using Applied Biosystems (ABI) fluorescence based technology using ABI Linkage Marker Set 2. This set contains 400 dinucleotide repeat markers at 10 centimorgan intervals with an average heterozygosity of 75%. Using 48 lane gels, containing an average of 672 genotypes per gel, we have concluded data gathering on the 164 families and a total of 166 000 genotypes have been checked by two genotypers. Since our study is mainly based upon affected sibling pairs we developed additional checks using a purpose written Microsoft Access database to give added quality assurance. These checks include evaluating whether all alleles with the same size have been called identically, comput- Conclusion There appears to be little difference in the dynamic ARI between the various tests and also between depressor and pressor stimuli. Increasing blood pressure levels do not appear to alter dynamic cerebral autoregulation in older people when measured by these methods.
ing our heterozygosity versus published data, mean and standard deviation of allele frequencies to spot gel-to-gel variation and any outlying alleles which may have been miscalled. We also track performance of the four ABI 377 machines used for genotyping and our technician's individual performance which alerts us to issues of quality and training needs. In addition, because we do not have full nuclear families we check at least 50 unlinked markers genome-wide for Mendelian inheritance using a programme called Relative.
Results and conclusion
From our 164 families comprising 190 affected sibling pairs these important data checks revealed we had 181 full sibling pairs (95% of our first screen), six half sibling pairs (3%) which can still be analysed but are not as informative. Most importantly, these checks revealed two completely unrelated siblings (1% of first screen) probably due to unknown adoption and one pair of undeclared monozygotic twins (0.5% of first screen) which had not been identified by phenotyping and were eliminated from further analysis. For technical reasons from our 166 000 genotypes we had to repeat 11 282 (6.7% of total), of these 3583 were interpretable on a single gel, but 7699 were typed on both gels. Of these 98.91% (7615) gave identical genotypes with mean difference in migration through the gel between the first and repeat gels of only 0.12 base pairs. These data from our Microsoft Access database confirm the robustness and reproducibility of this technology within the MRC BRIGHT study and offer a valuable approach for assuring data quality in family studies of complex disorders. Background Intima-media thickness (IMT) of the common carotid (CC) artery is associated with many cardiovascular risk factors and predicts increased risk of myocardial infarction and stroke. Large vessel diameter (D) is also associated with increased cardiovascular risk. As intima media area (IMA) is independent of distending pressure, it appears to be a better measure of vascular mass than IMT.
Regression of intima-media thickness and intima
Objective To compare the changes in the carotid artery in previously untreated hypertensive patients, during 1 year of antihypertensive therrapy with amlodipine or lisinopril.
Design and methods
This was a randomised, double-blind, parallel group, single centre study. Treatment with amlodipine (5-10 mg daily, n = 35) or lisinopril (5-20 mg daily, n = 34) was titrated according to BP response (target BP Ͻ140/90 mm Hg). Doxazosin (1-8 mg daily) and bendrofluazide (2.5-5 mg daily) were added if required. Bilat- Table 1 14 weeks 26 weeks 50 weeks Objective To determine whether essential hypertension (EH) can be cured in some patients by restoring blood pressure (BP) to normal values for 2 years at a young age.
Blood pressure and left ventricular hypertrophy in proteinuric glomerular disease
Background If vascular remodelling were a necessary cause rather than consequence of sustained hypertension, reversal of remodelling would reverse the hypertension itself in some patients. In these, normalisation of BP at an early stage in the development of hypertension should permit treatment to be withdrawn. Previous formal studies of treatment withdrawal have been in older patients, and the treatment target of 140/90 mm Hg is in the upper, skewed part of BP distribution where remodelling may not be reversed.
Methods Thirty-seven untreated patients, age 24 -51 years (mean 41), had their BP reduced from 159 ± 11/98 ± 5 mm Hg to 125 ± 9/75 ± 6 mm Hg by our AB/CD strategy of treatment rotation ± combination (Dickerson et al. Lancet 1999; 353: 2008 -2013 . After rotation (month on, month off) through ACEi, Beta-blockade, Ca ++ blockade, Diuretic, the better of 'AB' was combined, if necessary, with the better of 'CD'. The target of р135/85 mm Hg was the ͕mean + 1 s.d.͖ BP of 10 000 healthy controls. Resistant or intolerant patients had ␣-blockade or AIIRA added or substituted. Patients were seen at 3 monthly intervals for 2 years, and then all treatment was stopped. Patients continued to be seen 3 monthly, with an extra visit 1 month after stopping. In 12 patients, arterial stiffness was assessed at each visit during and after withdrawal, using the SphygmoCor™ analysis of the radial pulse wave to calculate augmentation index (AI). BP data was analysed by repeated measures, comparing BP 1 month after withdrawal with BP 1 month after the same treatment during rotation. Results Seventeen patients were controlled by one drug, 18 by two, and two by three. The primary drug was ACEi or beta-blockade in all but seven patients, where an AIIRA was substituted for ACEi. Treatment was restarted when BP rose above 140/90 mm Hg: in 21 patients by 3 months, in 30 by 6 months and 33 by 1 year. The rate of rise of BP was similar overall after 2 years of treatment as after 1 month during rotation, but slightly slower in patients for whom ACEi was best treatment ( Figure  1) ; by contrast, the BP rise was accelerated in patients requiring combination with diuretic ( Figure  2) . AI was 17.7 ± 12.7 on treatment, and unchanged following withdrawal. Objectives To determine whether the response to optimal antihypertensive treatment in high risk patients is affected by associated cardiovascular risk factors, such as diabetes.
Conclusions
Background INSIGHT is one of the first, fully blinded outcome trials comparing an 'older' with 'newer' class of antihypertensive. The primary classes, Ca ++ -blockade and Diuretic, are probably the optimal for older patients, whereas the second-line options, ACEi or Beta-blockade, are the optimal additions. The entry criteria required patients to have at least one of 10 additional risk factors, for which they were stratified in the dynamic randomisation. The number of patients with each risk factor permits us to determine, without confounding, whether the initial response or final blood pressure (BP) achieved after stepwise titration is influenced by age, gender, smoking, cholesterol, diabetes, atherosclerosis, LVH, or isolated systolic hypertension (ISH).
Methods Repeated measures analysis of variance was performed on the BP readings before and 2 weeks after randomised initial treatment to Step 1: nifedipine LA 30 mg or hydrochlorothiazide 25 mg + amiloride 5 mg;
Step 2: optional dose doubling (4 weeks); Steps 3 & 4: addition of atenolol 25/50 mg or enalapril 5/10 mg (8 & 12 weeks), and Step 5: any other third drug (18 weeks). Independent variables were each of the pre-stratified risk factors. The influences on the initial ⌬BP response to step 1 were analysed by multiple regression. Differences in BP (mm Hg, mean ± s.d.) are reported only when P Ͻ 0.01.
Results BP fell from 172 ± 15/99 ± 9 on placebo to 139 ± 12/82 ± 7 by the end of titration. DBP fell to Ͻ85 mm Hg in all the risk groups, and SBP to р 140 mm Hg in all but the diabetics. Gender, smoking and cholesterol had little or no influence on ⌬SBP or ⌬DBP, but target organ damage (LVH and atherosclerosis) significantly reduced responsiveness. A total of 1139 diabetics (mean age 65, 48% men) had wider pre-treatment pulse pressure (174/97 vs 171/98 mm Hg), smaller initial response (20 ± 16/9 ± 9 vs 21 ± 15/10 ± 8) and higher use of ments, although the opposing influences of ACEi and diuretic do imply a small role for AII in maintaining hypertension (HT). The findings contrast with the rapid reversal of secondary HT in many patients after removal of the cause. Our preliminary control data for AI suggest this parameter is at least 50% elevated in young patients with EH, and that arterial stiffness may be a primary abnormality which treatment cannot reverse. additional drugs (39% & 6% receiving Ͼ1 and Ͼ2 drugs, respectively, vs 28% and 3%) for a similar overall ⌬BP as 4530 non-diabetics (mean age 66, 48% men) (Figure 1a) . The initial fall of 22 ± 14/6 ± 8 in 1333 patients with ISH (age 67, basal BP 172 ± 11/88 ± 5) was slightly greater than that of 21 ± 15/11 ± 8 in patients with diastolic HT (age 65, basal BP 172 ± 16/102 ± 6); the final SBP was, however, slightly greater in the ISH patients (140 ± 12/78 ± 7 vs 138 ± 7/83 ± 7) (Figure 1b) . In all groups, patients requiring three drugs had smaller average responses to each drug, rather than resistance to the primary drug. Objective Polymorphisms of the epithelial sodium channel could cause high blood pressure by increasing renal sodium reabsorption. The T594M mutation is predicted to increase channel activity as it affects an important regulatory site whereas the G442V mutation is not expected to alter channel function. We therefore studied the frequencies and associations with hypertension of both the T594M and the G442V mutations of the ␤ subunit of the epithelial sodium channel in an unselected population of African origin.
Comment
Design and methods A population-based sample of 459 subjects (279 women), aged 40-59 years, of African descent was obtained from stratified random sampling of general practices' lists within a defined area of South London. They were all first generation immigrants. The prevalence of hypertension (BP у160 and/or 95 mm Hg or on drug therapy) was 43%. The mutations were detected using single strand conformational polymorphism technique (SSCP). The presence of the mutations was confirmed using direct sequencing of both strands on an ABI 377 automated sequencer. Objective To compare, in borderline hypertensives, the short-term effects on central aortic pressure and arterial stiffness of three classes of drugs that suppress the renin and/or sympathetic components of hypertension.
Results
Background Borderline hypertensives may be the preferred group for studying haemodynamic changes that cause rather than follow development of essential hypertension (EHT). There is increasing evidence that arterial stiffness is an early change; two manifestations of this, augmentation of the systolic blood pressure (SBP) by wave reflection, and pulse wave velocity (PWV), are readily measured using the technique of applanation tonometry over superficial arteries.
Methods Fourteen patients, age 40 ± 9 years, with a diastolic BP (DBP) between 80 and 95 mm Hg on three occasions over 3 months entered a three-part open-label crossover study of an ACE inhibitor (lisinopril, 10 mg), beta-blocker (bisoprolol, 5 mg) and centrally acting agent (moxonidine, 0.2 mg). Each drug was taken daily for 2 weeks, followed by T594M mutation in the whole population sample was 4.6%: the frequency of the G442V mutation was higher (27.0%). The frequency of the T594M mutation was twice as high amongst hypertensives compared with normotensives (6.6% vs 3.1%; P = 0.07). By contrast the frequency of the G442V mutation was similar in the two groups (28.7% vs 25.8%; P = 0.48). Adjustment for age, sex, body mass index, and the presence of diabetes did not alter these findings. There was one individual homozygous for the T594M mutation; there were 10 individuals homozygous for the G442V mutation. The analysis of allele haplotypes confirmed the potential importance of the T594M mutation over the G442V mutation in relation to hypertension in people of African origin.
Conclusions
The present study in a population of African origin shows that: (a) the T594M mutation is nearly six times less common than the G442V mutation; (b) the T594M mutation is associated with hypertension, whilst the G442V mutation is not. These results strongly support our previous findings on the T594M mutation in a case-control study, and point to this mutation as an important secondary cause of hypertension in people of African origin.
a minimum washout of 2 weeks. Brachial BP was measured by Datascope, and pulse wave analysis of the carotid and radial arteries, by Sphygmocor™, was used to estimate central aortic pressure (CAP), PWV between the sites, and augmentation index (AIx). Each parameter was measured before and after the three treatment periods, and the responses analysed statistically by repeated measures and multiple regression.
Results
The results are summarised in Table 1 . Beta-blockade lowered DBP more than ACEi (P Ͻ 0.05), and moxonidine was ineffective. Only beta-blockade reduced PWV, (P = 0.0003 after correction for heart rate). AIx was unaffected by any treatment; values were twice as high in women as men. The only significant predictor of BP response was PWV: SBP response to beta-blockade was greatest in patients with stiffer arteries (pcorr −0.81, P Ͻ 0.05).
Comment Short-term changes in arterial stiffness must be functional, not structural. Crossover studies This device is accurate according to the criteria of the British Hypertension Society's protocol, achieving grade B for both systolic and diastolic blood pressure. The device only comes in one size, and it is not known whether 'undercuffing' in the wrist may cause error which is well described with upper arm measurements. There is also potential for patients not to hold the device level with the heart when used away from medical supervision.
Objective The aims of this study were to determine: (1) The accuracy of the Omron Rx wrist monitor in patients with a range of body mass indexes (BMI), compared to appropriate upper arm cuffs for that individual; (2) To compare the variability of blood pressure measured with (a) wrist device (b) upper arm device, used in the home environment.
Method (1) Thirty-four patients with a wide range of BMIs were recruited and had sequential measurements made with wrist (Omron Rx), regular (23 × 12 cm) and large (32 × 17 cm) blood pressure cuffs on three occasions. The order of these were randomised. These were compared using t tests and BHS validation criteria (Bland-Altman plots). (2) Sixteen patients were trained to use an upper arm that this effect of beta-blockade could be mediated through its pronounced influence on PWV. The previously noted sex difference in AIx is probably due to greater wave reflection in shorter subjects.
(Omron 705CP) and wrist device (Omron Rx), and sent home to record alternate hourly measurements. Variation was compared between the two monitors using F test. Background Studies correlating physical activity with blood pressure (BP) level suggest that the fall in BP seen at night (the 'nocturnal dip') is due to cessation of physical activity rather than any intrinsic circadian rhythm in blood pressure. The nocturnal dip has clinical significance in hypertension, as a failure of BP to fall by at least 10% at night (nondipping) has been linked to increased cardiovascular morbidity, and has been suggested to be a marker of non-essential hypertension. Dipper status has been found to be poorly reproducible on repeat ambulatory BP monitoring (ABPM).
Objective The aim of this study was to define the relationship between physical activity and the magnitude of the nocturnal dip using an objective measure of physical activity levels. We also aimed to examine the influence of possible confounding variables on this relationship.
Design and methods
We simultaneously monitored 24-h ambulatory BP with the Quiet-Trak recorder, and assessed physical activity with a wrist-mounted piezoelectric accelerometer (Gaehwiler), in 434 consecutive patients referred to our clinic. Blood pressure was measured every 20 min during the daytime, while the activity monitor integrated an activity score between 0 and 250 arbitrary units every 10 sec. Mean activity scores for the 15 min preceding each BP reading were calculated; these were averaged to obtain daytime and nighttime activity means. Activity means were log transformed. Nocturnal dip in systolic BP (SBP) and diastolic BP (DBP) were regressed on mean daytime physical activity. Age, gender, smoking status, body mass index (BMI), clinic BP and mean night-time activity were added into a multiple linear regression.
Results
The patient group was heterogeneous in age (mean = 47.8, s.d. = 14.1), sex (49.2% male,
Towards a simpler and common protocol for the validation of blood pressure measuring devices
N Atkins and E O'Brien
Blood Pressure Unit, Beaumont Hospital, Dublin, Ireland
Objectives It is accepted that independent validation of blood pressure measuring devices is necessary, but the protocols of the BHS and AAMI, which have much in common, are expensive and difficult to perform because of the large number of subjects and the range of pressures demanded. In an attempt to unify the two protocols, and to simplify the validation procedures, we examined the data from 19 device validation studies performed by us to test how results would have been affected with smaller sample sizes and altered recruitment ranges. n = 207) and average 24-h BP (mean = 144/89 mm Hg, s.d. = 20/12); 45.8% (n = 202) of patients were on antihypertensive medication. A high rate of daytime activity was significantly associated with a high nocturnal dip in both SBP and DBP; conversely, low mean daytime activity was predictive of a small nocturnal dip. Increased night-time activity was significantly associated with a smaller percentage fall in BP. Increased age was associated with a smaller nocturnal dip in SBP and DBP; males had a greater nocturnal dip in SBP. Smoking status, BMI and clinic BP level were not associated with the extent of the fall in BP seen at night after adjustment for other factors (Table 1) .
Conclusions Daytime and night-time physical activity levels are independently predictive of the magnitude of the nocturnal dip in BP. Variability of physical activity may confound interpretation of 24-h ABPM, and contribute to the poor reproducibility of dipper status.
Methods
We examined data from 21 validation studies to examine how a reduction in sample size and the simplification of recruitment blood pressure ranges would have altered the results. Minor modifications to passing criteria were also examined to reflect this reduction and to determine if poor devices could be eliminated at an earlier stage.
Results
Range of pressures:
Experience has shown that recruiting subjects at the extremes of high and low (65) 75 (85) 90 (95) 99 All of 45 (60) 70 (80) 85 (90) 99 pressures (as recommended at present) is impractical. Furthermore, as blood pressure variability is greater at these extremes, sequential comparisons are often unreliable. The relaxation of these requirements to those shown in Table 1 , with an equal Background Systemic infection and inflammation are implicated in the development of atherosclerosis, and an acute infective or inflammatory episode transiently increases the risk of a cardiovascular event. However, the mechanisms which underlie these associations are not known. Since endothelial dysfunction underlies a variety of cardiovascular diseases, we examined the effect of a transient inflammatory stimulus on the function of the arterial endothelium in humans.
Acute systemic inflammation impairs endothelium-dependent dilatations in humans
Methods An inflammatory response was generated in healthy volunteers by an intramuscular injection of S. typhi capsular polysaccharide vaccine. In 12 subjects ultrasound was used to assess brachial artery dilatation in response to flow (flow-mediated dilatation; FMD) and to sublingual glyceryl trinitrate (GTN; conduit vessel response) and, in six subjects, venous occlusion plethysmography was used to number of subjects being recruited to each range, facilitates the validation procedure without unduly affecting results. Sample size: Both the AAMI and BHS protocols require a sample size of 85 subjects with three pairs of measurements each. Original power calculations were based on 85 pairs of measurements. But, as the sample size required to prove the accuracy of a difference decreases as that difference increases, a smaller sample is required to prove that a device is very inaccurate than is required to prove that a device is accurate. Our data support dividing the validation process into two phases. In a primary phase, three pairs of measurements are performed in 15 subjects in the above pressure ranges and a device failing this phase (see Table 2 ) is eliminated from further testing. One passing it proceeds to a secondary phase, in which a further 18 subjects (total 33) are recruited, in whom comparisons must fulfil the criteria shown in Table 2 .
Conclusion These alterations did not substantially alter the results of any of our studies but they would have greatly simplified the validation process.
measure forearm blood flow during intra-arterial infusion of incremental doses of the 'endotheliumdependent' dilators acetylcholine (ACh) and bradykinin (BK) and the 'endothelium-independent dilators' GTN and verapamil (resistance vessel response). Resistance vessel responses were assessed 16 h before, and again 8 h and 32 h after vaccination. Conduit vessel responses were assessed 16 h before and again 8 h after vaccination.
Results Following vaccination, white cell count rose from 4.0 (± 0.3) × 10 9 /L at baseline to 6.1 (± 0.5) × 10 9 /L at 8 h (P Ͻ 0.01), serum levels of interleukin (IL)-6 rose from 2.1 (± 0.4) pg/ml pre-vaccine to 5.8 (± 3.2) pg/ml 8 h post vaccine (P = 0.07), and the level of IL-1 receptor antagonist rose from 188.0 (± 35.9) pg/ml to peak at 593.6 (± 198.0) pg/ml after 3 h, a 191% increase from baseline (P Ͻ 0.05). There was no change in temperature, heart rate, blood pressure, the plasma levels of IL-1 or tumour necrosis fasctor ␣, or in resting forearm blood flow.
Resistance vessel response Prior to vaccination, there was a dose-dependent increase in forearm blood flow to all the agonists studied. After vaccination, there was a profound, selective, but temporary blunting in the dilator response to endotheliumdependent dilators BK (Figure 1 ) and ACh (data not shown) with no significant change in the response to GTN (Figure 1) or verapamil (data not shown) . In the absence of vaccination, there was no change in response to either endothelium-dependent or endothelium-independent dilators when studies were conducted 24 h apart (n = 5). − in some animal models may contribute to endothelial dysfunction, vascular hypertrophy and hypertension in these animals.
Conduit vessel response
Aims
The objectives were to investigate (1) the cellular and enzymatic sources of O 2 − production within human blood vessels, and (2) the effects of vasoactive agents such as angiotensin II on O 2 − generation.
Methods Internal mammary arteries (IMA), radial arteries (RA) and saphenous veins (SV) were collected from patients undergoing coronary artery bypass surgery. Blood vessels were divided into 5 mm rings and incubated in Hepes buffer in the absence (control) or presence of a non-specific NADH/NADPH oxidase inhibitor diphenyleneiodonium (DPI) 10 M at 37°C. O 2 − production was quantified by lucigenin enhanced chemiluminescence in a liquid scintillation counter. Absolute counts were corrected for wet weight of tissue and plotted against a xanthine/xanthine oxidase calibration curve. Superoxide dismutase (SOD) proteins were quantified by Western blotting using actin as an internal control. Results are shown as mean ± s.e.m. or as % of control to facilitate comparison between groups. Statistical analyses were performed by use of the Wilcoxon Signed-Ranks Matched Pairs tests for non-parametric data.
Results In IMA and RA, O 2 − generation was 1200 ± 310 (n = 28) and 910 ± 260 (n = 7) respectively compared to 290 ± 30 pmoles/mg/min in SV impairment in FMD by 8 h following vaccination (mean FMD was 6.5% ± 0.5% pre vaccination vs 5.0 ± 0.5% 8 h post vaccination, P Ͻ 0.05). In contrast, there was no difference in the GTN response at these two time points (9.5 ± 0.7% at baseline vs 9.5 ± 0.9% at 8 h).
Conclusions Vaccination with S. typhi capsular polysaccharide vaccine generates a mild systemic inflammatory response which produces temporary but substantial dysfunction of the arterial endothelium. The dysfunction is seen in both resistance and conduit vessels, to both physical and pharmacological dilator stimuli. If the systemic inflammation which follows naturally-occurring infective or inflammatory episodes perturbs the normal function of the vascular endothelium in the same way, this might contribute to the observed association between infection and inflammation and the enhanced risk of an acute cardiovascular event.
(n = 53). Incubation of both arteries and veins with DPI 10
− generation by 41 ± 10% in arteries (P = 0.037) and by 34 ± 6% in veins (P = 0.009). Endothelial removal attenuated O 2 − production in 68% of arteries and 73% of veins. L-NAME 10 −4 M had similar effects to endothelial removal causing a reduction in O 2 − generation in 60% of arteries and 69% of veins. Angiotensin II increased O 2 − production in a dose dependent manner in arteries but had no effect in veins (Table 1) . A time effect was also observed. All 10 −6 M had no effect on O 2 − production after 15 min incubation, but increased O 2 − production after 1 h to 183% of control (P Ͻ 0.01). In contrast noradrenaline caused no increase in O 2 − generation in either IMA or SV. Immunoblotting indicated that the total amount of SOD protein was similar in arteries and veins. Further analysis showed that the relative proportions of CuZn and Mn SOD were 55% and 45% respectively in arteries with reciprocal contributions of these enzymes in veins.
Conclusions
We report for the first time that O 2 − levels are greater in human arteries than veins. The higher O 2 − levels in arteries are most likely due to increased synthesis rather than decreased scavenging. Endothelial nitric oxide synthase and Background Insulin-mediated vasodilation, which is dependent on endothelial nitric oxide (NO) synthesis, is enhanced by local tissue glucose uptake, suggesting that insulin-mediated glucose uptake is important for endothelial cell metabolic function. In the present study, we assessed insulin sensitivity, insulin-mediated vasodilation and endothelial function in control subjects (C), non-diabetic patients with mild hypertension (HT), and normotensive patients with diet-controlled type 2 diabetes (DM).
Methods and results
Twenty-seven subjects attended on three separate occasions for measurement of whole-body insulin sensitivity [euglycaemic clamp (1.5 mU/kg/min)], insulin-mediated vasodilation [forearm plethysmography (5mU/min)], and basal endothelial NO synthesis [intra-arterial N Gmonomethyl-L-arginine (4 mol/min)]. The groups (C vs HT vs DM; mean ± s.d.) were well matched for age (53 ± 8.1 vs 55 ± 8.7 vs 59 ± 10.2 years) and BMI (26.8 ± 3.3 vs 26.5 ± 5.1 vs 26.9 ± 3.9 kg/m 2 ). By design, diastolic BP was higher in HT (80 ± 7.8 vs 101 ± 6.9 vs 81 ± 9.0 mm Hg) and fasting glucose was higher in DM (5.1 ± 0.6 vs 4.8 ± 0.3 vs 7.7 ± 1.2 mmol/l). Insulin sensitivity (C 7.3 ± 1.82, HT Background Hypertension is associated with increased urinary calcium (Ca) excretion, irrespective of sodium intake. This may be due to either an underlying renal tubular defect or to an effect of volume expansion. In addition, a high sodium intake increases both urinary Ca and blood pressure (BP). This may explain the higher risk of kidney stones and bone demineralisation seen in hypertensives. However, it is not clear whether this effect is due to diet, and if it is modified by gender or ethnic origin. We therefore examined the independent effects of BP, urinary sodium (Na) excretion, gender and ethnic origin upon both daily and fasting urinary Ca excretions in a population-based study.
Epidemiology
Methods Out of 1577 individuals taking part in a cross-sectional survey in South London, 743 were activity of the renin/angiotensin system may promote increased oxidative stress in the cardiovascular system.
6.3 ± 1.57, DM 5.1 ± 1.24 mg/kg/min), insulinmediated vasodilation (C 17.1 ± 16.8%, HT 17.2 ± 16.5%, DM 12.3 ± 19.2%) and vasoconstriction to L-NMMA (C 37.9 ± 15.3%, HT 33.6 ± 8.4%, DM 37.5 ± 6.9%) did not differ significantly among these small groups of subjects. Analysis of pooled data revealed positive correlations between insulin sensitivity and endothelial function (r = 0.44, P Ͻ 0.05), insulin sensitivity and insulin-mediated vasodilation (r = 0.46, P Ͻ 0.05), and insulinmediated vasodilation and endothelial function (r = 0.52, P Ͻ 0.01). These correlations were not explained by 'clustering' of diagnostic groups. In multiple regression analyses, insulin sensitivity was best predicted by a model including age, BMI, triglycerides and insulin-mediated vasodilation (adjusted R 2 59%); insulin-mediated vasodilation was best predicted by a model including endothelial function, age and BMI (adjusted R 2 42%).
Conclusions Significant relationships were demonstrated not only between insulin's metabolic and vascular actions but also between insulin action and basal endothelial NO production. Insulin's role as a physiological regulator of endothelial function may be independent of blood pressure and the prevailing level of glycaemia.
considered for the present analysis (407 women, 336 men) as they were all untreated, had provided a complete 24 h urine collection, and had had all measurements of anthropometry, BP, urinary Na and Ca. They were 277 whites (W), 227 of African origin (Afr) and 239 South Asians (SA). Comparisons were also carried out in the 690 participants who also provided complete 3 h fasting urine collections. Multivariate analysis was carried out using a general linear model. Estimates of slopes and adjusted means were calculated.
Results Twenty-four hour urinary Ca excretion was significantly associated with gender (menϾwomen, P Ͻ 0.001), ethnic origin (WϾSAϾAfr, P Ͻ 0.001), positively with mean BP (P = 0.015) and 24 h urinary Na (P Ͻ 0.001). After adjustment for age, gender, ethnic origin, BP and urinary Na, 24 h urinary Ca was still significantly and independently associated with all these variables but gender. Adjusted mean 24 h Ca excretions were 4.62 (0.11) mmol/d (m[se]) in white subjects, 3.33 (0.12) in South Asians and 3.14 (0.13) in people of African origin (P Ͻ 0.001). A 100 mmol higher Na excretion predicted a 1.04 mmol higher daily Ca excretion (P Ͻ 0.001), and a 20 mm Hg higher mean BP predicted a 0.44 mmol higher Ca excretion. These slopes were not significantly different by ethnic group. The differences in urinary Ca between ethnic groups did not differ when fasting urinary Ca excretion was used instead. Background Most studies on blood pressure during exercise have focused on systolic blood pressure (SBP). Diastolic blood pressure (DBP) measurements during exercise are rarely reported perhaps because of concern relating to the accuracy of such measurements. We examined the reproducibility of SBP and DBP measurements taken during exercise by mercury sphygmomanometry (Korotkoff sounds 1 and 4) and compared mercury sphygmomanometer readings taken by a trained observer with intra-arterial BP. We then examined whether there is an association between metabolic risk factors for cardiovascular disease and changes in BP during mild exercise. Metabolic factors may influence BP through effects on vascular reactivity and such effects may influence DBP during exercise more strongly than at rest.
Methods Study 1: Six healthy normotensive men attended a temperature controlled clinical laboratory and rested supine while a 22G arterial cannula was inserted into the radial artery of the non-dominant arm under local anaesthetic. This was attached to a saline-filled catheter and transducer (Uniflow, Baxter, The Netherlands). BP was measured by a single trained observer on the dominant arm using mercury sphygmomanometry and an appropriate sized cuff according to British Hypertension Society guidelines. BP was measured at 3-min intervals at rest and during exercise on a bicycle ergometer for 3 mins at 50 W, 75 W and 100 W. Measurements using mercury sphygmomanometry alone were obtained in a further eight healthy normotensive subjects (five men, three women) on three occasions. Study 2: 75 healthy active men (18-66 years) were investigated after an overnight fast. Blood was taken for serum lipids and insulin resistance was estimated from the fasting glucose × insulin product. They then completed the same exercise protocol as in study 1 and BP was measured by mercury sphygmomanometry as before. The observer was not mol/min in people of African origin; P Ͻ 0.001 for white subjects vs South Asian or African). The degree of association with both BP and urinary Na also did not vary.
Conclusions
These results indicate that BP, salt intake and ethnic origin are independent predictors of urinary Ca excretion in an unselected population. These relationships are unlikely to be the result of differences in Ca intake or intestinal Ca absorption as they are seen also after an overnight fast, suggesting that they may reflect differences in renal tubular handling. The estimated effects of either BP or Na intake on urinary Ca excretion, sustained over many years, may be responsible for significant effects on total body Ca balance.
aware of subject's metabolic characteristics at the time of the study. Associations between BP (resting BP and the change in BP during exercise) and metabolic factors was sought using linear regression analysis.
Results Study 1: Sphygmomanometric and intraarterial measurements of DBP did not differ significantly during exercise: mean (s.d.) difference 5 (7) and 3 (9) mm Hg at 50 and 100 W respectively. Mean within subject coefficients of variation for SBP by sphygmomanometer were 6.9 and 5.9% at 50 and 100 W respectively and for DBP were 5.6 and 4.7% at 50 and 100 W respectively. Study 2: SBP and DBP at rest were not significantly correlated with serum concentrations of total cholesterol or insulin resistance. The change, from resting values, in DBP (⌬DBP) but not SBP, during exercise was correlated with serum cholesterol (R = 0.47, P Ͻ 0.0001 for each work load) and with insulin resistance (R = 0.38, P Ͻ 0.01 for each work load). The mean rise in DBP on exercise for all work loads was 2.9 mm Hg [95% CI: 1.8-4.1] per mmol/L rise in total cholesterol. Serum cholesterol and insulin resistance were the only independent predictors of the ⌬DBP during exercise in a stepwise regression model incorporating age, body mass index, serum total cholesterol, triglycerides, HDL-cholesterol, insulin resistance and heart rate during exercise.
Conclusions Sphygmomanometric measurements of DBP obtained by a trained observer during low work load bicycle ergometry are reproducable and approximate intra-arterial measurements. Changes in DBP during such exercise are strongly associated with serum concentrations of total cholesterol and with insulin resistance. This may contribute to the development of hypertensive complications in dyslipidaemic or insulin resistant patients. There is increasing interest in the effect of hypertension on cognitive function in the elderly, with suggestions that blood pressure lowering treatment in older hypertensive subjects may reduce the incidence rate of dementia (Forette et al. Lancet 1998; 352: 1347 -1351 . A majority of studies report impairment in cognitive function in older hypertensives compared to normotensive controls. However, inclusion of patients taking antihypertensive therapy or with previous stroke confounds interpretation of these data. A study in rigorously screened older subjects with hypertension found impairments in attention and psychomotor speed (Kalra et al. J Hum Hypertens 1993; 7: 279-284) . We examined differences in cognitive function in elderly hypertensive and normotensive subjects using a more extensive computerised assessment battery, previously validated in a number of other conditions. Subjects aged 70-89 years were recruited from 10 local general practices. Blood pressure status was defined on the mean of last two readings on the third occasion during a 6-week period; hypertensive, BP 160-179 systolic and/or 90-99 mm Hg diastolic, normotensive subjects BP Ͻ 150/80 mm Hg. Subjects with known cognitive impairment, depression, previous stroke, on blood pressure lowering therapy or benzodiazepines were excluded. A computerised cognitive assessment battery (Cognitive Drug Research) was administered to subjects on the third visit after training. The battery comprised eight tests; simple and choice reaction time, attention and concentration (number vigilance and memory scanning), immediate and delayed word recognition, picture recognition, spatial memory.
Cognitive performance in normotensive and hypertensive older subjects
Sixty-seven hypertensives (27 female, 75 ± 4 years, 162 ± 9/89 ± 7 mm Hg) and 67 normotensives 6.1 High blood pressure is associated with bone mineral loss in elderly white women Background Animal, clinical and epidemiological evidence suggests that high blood pressure is associated with abnormalities in calcium metabolism (such as hypercalciuria and secondary hyperparathyroidism). Sustained calcium loss may lead to a greater bone mineral loss in people with high blood pressure.
Methods We examined whether blood pressure predicts changes in bone mineral density among white elderly women in a prospective cohort study (The Study of Osteoporotic Fractures). The present analysis is restricted to 3676 women examined in 1988-1990 (age 73 ± 4 [mean ± s.d.] years, range 66-91; weight 65.3 ± 11.5 kg; BP 137/75 ± 17/9 mm Hg) (29 female, 75 ± 4 years, 131 ± 10/74 ± 6 mm Hg) were studied. Years in education (10 ± 2 vs 10 ± 2 years) and MMSE score (28 ± 1 vs 28 ± 1) were similar. Prevalence of comorbidities was; myocardial infarction 7 vs 6%, atrial fibrillation 6 vs 1%, diabetes 4 vs 3%, peripheral vascular disease 6 vs 1%. Concomitant medication was similar (aspirin 19 vs 19%, warfarin 1 vs 0%). Hypertensive subjects had impaired cognitive performance in four of the eight domains tested. Data shown are means and (s.d.) (Table 1) . These results confirm that hypertension in older subjects is associated with impaired cognitive performance in a broad range of areas. Since premorbid cognitive function is a risk factor for dementia, hypertension may place older subjects at increased vulnerability for developing dementia. who were not on thiazide diuretics. Average followup was 3.5 years. Anthropometry, blood pressure and bone mineral density at the femoral neck were measured at the baseline and bone densitometry repeated 3.5 years later by dual X-ray absorptiometry.
Results
On average there was a loss of femoral neck bone mineral of just over 3 mg/cm 2 /yr, equivalent to an annual loss of 0.5%. Both absolute and relative femoral neck bone losses were significantly associated with age and systolic BP, was twice as great in smokers and twice as slow in HRT users. After adjustment for age, initial bone mineral density at the femoral neck, weight and weight change, smoking and regular use of HRT, the rate of bone loss at the femoral neck increased with the levels of blood pressure. In the quartiles (Q) of systolic blood pressure, bone losses increased from 2.26 (95% CI 1.48-3.04) mg/cm 2 /yr in Q 1 to 3.45 (2.79-4.11) in Q 2 to 3.13 (2.44 -3.82) in Q 3 to 3.79 (3.13-4.45) in Q 4 (P = 0.03). These are equivalent to percentage losses of 0.34 (0.20-0.46), 0.53 (0.43-0.63), 0.50 (0.40-0.60) and 0.59 (0.49-0.69) percent/yr, respectively (P = 0.02). Women with a systolic blood pressure of 148 mm Hg or more (Q 4 ) had a rate of bone loss at the femoral neck almost twice as great compared to those with levels below 124 mm Hg (Q 1 ). There was no significant interaction with age (P = 0.59 and P = 0.61 for absolute and relative changes, respectively). Background Cigarette smoking has been reported to cause an acute rise in blood pressure (BP). Nevertheless, some epidemiological studies have found lower mean BP levels in smokers than in never-or ex-smokers. The aim of this study was to investigate any systematic difference in blood pressure levels of smokers and non-smokers using data from the Health Survey for England (HSE), an annual survey that provides information on the health status of a representative sample of the English population.
Methods We studied 33 860 people (47% men) aged 16 and above combining HSE data from 1994 to 1996. 27% of men and 25% of women were current smokers. Clinical examination included three sitting BP measurements using the Dinamap 8100 monitor (mean of the last two recordings used in analyses), body weight, height and a blood sample. Data were adjusted for age and subsequently for other confounders, body mass index (BMI), social class, and alcohol intake. The odds (and 95% CI) of being hypertensive (using both definitions, SBP у160 mm Hg or DBP у95 mm Hg or on antihypertensive medication; and SBP у140 mm Hg or DBP у90 mm Hg or on antihypertensive medication) were calculated by logistic regression.
The age-adjusted mean SBP and DBP for men and women are shown in Table 1 . After further controlling for confounders, among men, heavy smokers (у20 cigs/day) had significantly higher SBPs compared with non-smokers but no significant differences were observed in DBP. Among women pertensive medication (n = 623) did not alter the results. Similar but not significant trends were seen for diastolic blood pressure. However, significant interactions with age (P = 0.04 and P = 0.02, respectively) indicate that, for diastolic blood pressure, the association is only seen in women under 75 years.
Conclusions
The present study shows that higher blood pressure amongst elderly white women is a significant and independent predictor of bone mineral loss at the neck of femur. The mechanism underlying this association is not known but may reflect greater calcium losses associated with high blood pressure. This mechanism may contribute to the risk of hip fractures. the lower mean SBP in light smokers (Ͻ10 cigs/day) was still of borderline significance and light smokers also had significantly lower DBP than non-smokers. The odds of being hypertensive were not significantly higher in current or ex-smokers than nonsmokers, after controlling for potential confounders.
Conclusions These data show no significant differences in BPs between non-smokers and all current smokers. However after adjustment for confounders heavy smokers tended to have higher BPs than nonsmokers (significant for male SBP) and in women, light smokers had lower BP levels than non-smokers. Different findings between men and women may be partly accounted for by the complex interrelation between smoking, alcohol intake and BMI despite adjusting data for these variables. with a single BP to determine whether or not it was elevated (у90 mm Hg phase IV diastolic, BP4). If it was, two further readings on separate occasions were taken to determine if the patient had hypertension (two or three elevated readings out of three) or transient hypertension (one elevated reading out of three). Newly diagnosed hypertensives, transients and previously known hypertensives were matched with controls for age and sex and registered for mortality follow-up. We report the bias due to number preference in screening BP in this study, its relationship to patient characteristics and mortality rates.
Results High terminal digit '0' preference and low 6.4 Prevalence of coronary heart disease within a population of 901 829 sampled in the United Kingdom, and level of secondary prevention of coronary heart disease among those identified Purpose Several small studies have been published recently which document the prevalence of coronary heart disease (CHD) in different regions within the United Kingdom (UK). The present survey was undertaken nationwide to define the extent of CHD in the community and assist family doctors to audit whether measures for secondary prevention for individuals with CHD were being addressed in their practice.
Methods A total of 548 doctors working in 137 medium to large general practices took part. Twelve research nurses spent 18 months collecting the data, from March 1997 to September 1998. The average total number of patients in each practice was 7215, with an average of four physicians in each practice.
Results From a total number of 901 829 individuals, the medical records of 24 431 patients were identified as having CHD. The prevalence therefore was 2.7%, ie, each physician looked after about 50 patients with established CHD; 64.6% of patients were aged 60-79 years; and 17.1% were 80 or older;
'2' preference was present in 4th phase diastolic (28.2%, 15.0% respectively) fifth phase diastolic (31.4%, 13.4%) and systolic (30.4%, 16.5%) pressure in the first screening BP. This affected six out of seven participating practices. The number '88' in BP4 at screening was over-represented compared with expected in six out of seven practices, with a prevalence range of 5.7% to 10.8%. The exception was a practice where 60.4% of the readings ended in zero. There was an excess number of deaths for females at 88 mm mercury (compared with 80-87 mm and 90-97 mm) but not for males. Analysis using the Cox proportional hazards method adjusting for age, BMI, smoking status and systolic BP confirms a significant interaction between sex and diastolic BP band (P = 0.009) on risk of mortality. For females BP4 of 88 compared with BP4 90-97 mm confers a relative risk of 2.16 (P = 0.007) and for males 0.6 (P = 0.05). The corresponding results for BP4 of 88 compared with 80-87 were 1.94 (P = 0.01) in women and 0.76 (P = 0.29) in men.
Conclusion Mortality was worse than expected for female patients who had a BP4 of 88 mm at screening but not for males. This suggests that number preference in the GPHSG study led to women hypertensives being mis-classified into the normotensive group with a consequential higher mortality.
59.5% were male. Table 1 shows the distribution of disease and the level of secondary prevention.
Conclusions High proportions of patients in the UK with established CHD have inadequate secondary preventive measures: 86% have high cholesterol levels, or have never had it measured; 23% continue Background Elevated blood pressure (BP) is well recognised in the acute stroke period, though its management is a matter of some debate. However, BP reduces spontaneously in the majority of patients, and acute antihypertensive therapy may adversely affect the viability of the ischaemic penumbra particularly in the presence of cerebrovascular dysautoregulation and autonomic dysfunction. Nonetheless, sustained hypertension risks cerebral oedema and haemorrhagic transformation. Furthermore, elevated BP within the first 24 h of ictus has been associated with increased risk of death, dependency and neurological deterioration at 30 days, though any relationship with long-term outcome is less clear.
Objectives To investigate the relationship between BP recorded within the first 24 h of ictus by casual and 24-h techniques with long-term mortality.
Methods A total of 235 patients (123 male) of median age 73 years (95% central range 45 to 88) admitted within 24 h of ictus underwent casual BP and 24-h BP monitoring using Spacelabs 90207 recording at 15 min intervals. Mortality was recorded over a median follow-up period of 1031 days (range 250 to 2818) from medical records. Preselected criteria recorded within 24 h of ictus were used to predict subsequent mortality using Cox's proportional hazards modelling.
Results Casual and 24-h BP results measured 6.6 ACE inhibitors and mortality at the Glasgow Blood Pressure Clinic We have reported previously that in hypertensive patients attending the Glasgow Blood Pressure Clinic, treatment with ACE inhibitors was associated with a reduction in incident and fatal cancer (Lever AF et al. Lancet 1998; 352: 179-184) . The objective of this study was to assess the influence of ACE inhibitors (ACEIs) on other causes of death in the same population.
The Glasgow Blood Pressure Clinic holds on its computer database information on 11 000 hypertensive patients. Each is record-linked with the Registrar General Scotland for information on deaths and cause of death. Three general populations have been used as controls: the West of Scotland (2.7 m data is being used to generate a model for health promotion in CHD to be applied at the level of general practice. Table 1 . Sex, white cell count and glucose were not associated with mortality. On multiple variable Cox's proportional modelling, only 24-h SBP (vs Ͻ140; 140-159, HR 0.9 (0.5, 1.7); у160, HR 2.0 (1.1, 3.4) and age (vs р66: 73-80, HR 2.4 (1.1, 5.3); у80, HR 2.8 (1.3, 6.2) were independently associated with an increased hazards ratio.
Conclusions Twenty-four hour, not casual, SBP measured within 24 h of ictus is independently associated with increased mortality over a median follow-up period of over 3 years. subjects), 15 411 middle-aged subjects of Renfrew and Paisley (towns close to Glasgow) surveyed in the 1970s and the population of Glasgow (around 750 000). ACEIs were first prescribed at the Clinic in 1980. Between 1 January and 31 December 1995, 5207 patients received prescriptions for ACEIs or other antihypertensive drugs. This report describes a retrospective cohort study of this population. Relative risk (RR) of non-cancer mortality in ACEItreated patients and never ACEI-treated patients was examined by reference to expected risk in the Glasgow control population adjusted for age, sex and year of follow-up. The results are summarised in Table 1 . Non-cancer mortality was reduced in hypertensive patients treated with ACEIs. Significant reductions were seen for all cause mortality, cardiovascular and CHD mortality. There were no significant differences between the groups in renal function, blood sugar, serum cholesterol or social class. More ACEI treated patients received lipid-lowering (6.0% vs 3.2%) and anti-platelet (27.8% vs 16.0%) medication but entry and final blood pressure were significantly higher in the ACEI group; more patients with diabetes and on diabetic medication were treated with ACEIs. These differences are unlikely to account for this apparent survival advantage in patients receiving ACEIs.
This study provides preliminary evidence that mortality from all causes and cardiovascular diseases may be reduced in hypertensive patients prescribed ACEIs. These findings complement the results of prospective studies with ACEIs (Hansson L et al. Lancet 1999; 353: 611-616) . The duration of follow-up in this population may have allowed the demonstration of benefits not apparent in relatively short-term outcome trials.
